nodes	percent_of_prediction	percent_of_DWPC	metapath
Amantadine—Suicide—Sorafenib—thyroid cancer	0.0152	0.022	CcSEcCtD
Amantadine—Completed suicide—Sorafenib—thyroid cancer	0.0134	0.0195	CcSEcCtD
Amantadine—Depressed level of consciousness—Vandetanib—thyroid cancer	0.0113	0.0164	CcSEcCtD
Amantadine—Cardiac failure—Vandetanib—thyroid cancer	0.0087	0.0126	CcSEcCtD
Amantadine—Lethargy—Vandetanib—thyroid cancer	0.00866	0.0126	CcSEcCtD
Amantadine—Cardiac arrest—Vandetanib—thyroid cancer	0.00807	0.0117	CcSEcCtD
Amantadine—GRIN2C—thyroid gland—thyroid cancer	0.00746	0.0953	CbGeAlD
Amantadine—Dysphagia—Vandetanib—thyroid cancer	0.00734	0.0106	CcSEcCtD
Amantadine—Neutropenia—Vandetanib—thyroid cancer	0.00686	0.00995	CcSEcCtD
Amantadine—Photosensitivity reaction—Vandetanib—thyroid cancer	0.0067	0.00971	CcSEcCtD
Amantadine—GRIN2C—head—thyroid cancer	0.00662	0.0845	CbGeAlD
Amantadine—Eczema—Sorafenib—thyroid cancer	0.00637	0.00924	CcSEcCtD
Amantadine—Cardiac failure congestive—Sorafenib—thyroid cancer	0.00631	0.00916	CcSEcCtD
Amantadine—Renal failure acute—Sorafenib—thyroid cancer	0.0062	0.00899	CcSEcCtD
Amantadine—GRIN2D—head—thyroid cancer	0.00615	0.0786	CbGeAlD
Amantadine—Cardiac failure—Sorafenib—thyroid cancer	0.00587	0.00851	CcSEcCtD
Amantadine—Urinary tract disorder—Vandetanib—thyroid cancer	0.0058	0.00841	CcSEcCtD
Amantadine—GRIN3A—head—thyroid cancer	0.00579	0.0739	CbGeAlD
Amantadine—Urethral disorder—Vandetanib—thyroid cancer	0.00576	0.00835	CcSEcCtD
Amantadine—Visual impairment—Vandetanib—thyroid cancer	0.00566	0.00821	CcSEcCtD
Amantadine—Eye disorder—Vandetanib—thyroid cancer	0.00549	0.00796	CcSEcCtD
Amantadine—GRIN1—head—thyroid cancer	0.00548	0.07	CbGeAlD
Amantadine—Cardiac disorder—Vandetanib—thyroid cancer	0.00545	0.0079	CcSEcCtD
Amantadine—Angiopathy—Vandetanib—thyroid cancer	0.00533	0.00773	CcSEcCtD
Amantadine—Mediastinal disorder—Vandetanib—thyroid cancer	0.00529	0.00767	CcSEcCtD
Amantadine—Arrhythmia—Vandetanib—thyroid cancer	0.00525	0.00761	CcSEcCtD
Amantadine—GRIN2B—head—thyroid cancer	0.00523	0.0668	CbGeAlD
Amantadine—Body temperature decreased—Epirubicin—thyroid cancer	0.0052	0.00754	CcSEcCtD
Amantadine—Hypothermia—Epirubicin—thyroid cancer	0.0052	0.00754	CcSEcCtD
Amantadine—Alopecia—Vandetanib—thyroid cancer	0.00519	0.00752	CcSEcCtD
Amantadine—Mental disorder—Vandetanib—thyroid cancer	0.00515	0.00746	CcSEcCtD
Amantadine—Malnutrition—Vandetanib—thyroid cancer	0.00511	0.00741	CcSEcCtD
Amantadine—Dysphagia—Sorafenib—thyroid cancer	0.00495	0.00718	CcSEcCtD
Amantadine—Vision blurred—Vandetanib—thyroid cancer	0.00482	0.00699	CcSEcCtD
Amantadine—Hypothermia—Doxorubicin—thyroid cancer	0.00481	0.00698	CcSEcCtD
Amantadine—Body temperature decreased—Doxorubicin—thyroid cancer	0.00481	0.00698	CcSEcCtD
Amantadine—Tremor—Vandetanib—thyroid cancer	0.00479	0.00694	CcSEcCtD
Amantadine—Neutropenia—Sorafenib—thyroid cancer	0.00463	0.00671	CcSEcCtD
Amantadine—GRIN2A—head—thyroid cancer	0.00457	0.0584	CbGeAlD
Amantadine—Keratitis—Epirubicin—thyroid cancer	0.0045	0.00652	CcSEcCtD
Amantadine—Convulsion—Vandetanib—thyroid cancer	0.00443	0.00642	CcSEcCtD
Amantadine—Hypertension—Vandetanib—thyroid cancer	0.00441	0.0064	CcSEcCtD
Amantadine—Anxiety—Vandetanib—thyroid cancer	0.00434	0.00629	CcSEcCtD
Amantadine—Unspecified disorder of skin and subcutaneous tissue—Vandetanib—thyroid cancer	0.00432	0.00627	CcSEcCtD
Amantadine—Hypokinesia—Epirubicin—thyroid cancer	0.00432	0.00626	CcSEcCtD
Amantadine—DDC—head—thyroid cancer	0.00427	0.0546	CbGeAlD
Amantadine—Dry mouth—Vandetanib—thyroid cancer	0.00426	0.00617	CcSEcCtD
Amantadine—SIGMAR1—saliva-secreting gland—thyroid cancer	0.00424	0.0542	CbGeAlD
Amantadine—Paralysis—Epirubicin—thyroid cancer	0.0042	0.00608	CcSEcCtD
Amantadine—Oedema—Vandetanib—thyroid cancer	0.00417	0.00605	CcSEcCtD
Amantadine—Keratitis—Doxorubicin—thyroid cancer	0.00416	0.00603	CcSEcCtD
Amantadine—Nervous system disorder—Vandetanib—thyroid cancer	0.00409	0.00593	CcSEcCtD
Amantadine—MAOB—saliva-secreting gland—thyroid cancer	0.00406	0.0519	CbGeAlD
Amantadine—Skin disorder—Vandetanib—thyroid cancer	0.00405	0.00588	CcSEcCtD
Amantadine—Hypokinesia—Doxorubicin—thyroid cancer	0.004	0.00579	CcSEcCtD
Amantadine—Urinary tract disorder—Sorafenib—thyroid cancer	0.00391	0.00567	CcSEcCtD
Amantadine—Urethral disorder—Sorafenib—thyroid cancer	0.00388	0.00563	CcSEcCtD
Amantadine—Paralysis—Doxorubicin—thyroid cancer	0.00388	0.00563	CcSEcCtD
Amantadine—Insomnia—Vandetanib—thyroid cancer	0.00377	0.00547	CcSEcCtD
Amantadine—Paraesthesia—Vandetanib—thyroid cancer	0.00375	0.00543	CcSEcCtD
Amantadine—Dyspnoea—Vandetanib—thyroid cancer	0.00372	0.00539	CcSEcCtD
Amantadine—Cardiac disorder—Sorafenib—thyroid cancer	0.00368	0.00533	CcSEcCtD
Amantadine—Dyspepsia—Vandetanib—thyroid cancer	0.00367	0.00532	CcSEcCtD
Amantadine—Decreased appetite—Vandetanib—thyroid cancer	0.00363	0.00526	CcSEcCtD
Amantadine—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.0036	0.00522	CcSEcCtD
Amantadine—Fatigue—Vandetanib—thyroid cancer	0.0036	0.00522	CcSEcCtD
Amantadine—Angiopathy—Sorafenib—thyroid cancer	0.00359	0.00521	CcSEcCtD
Amantadine—Mediastinal disorder—Sorafenib—thyroid cancer	0.00357	0.00518	CcSEcCtD
Amantadine—Constipation—Vandetanib—thyroid cancer	0.00357	0.00517	CcSEcCtD
Amantadine—Arrhythmia—Sorafenib—thyroid cancer	0.00354	0.00513	CcSEcCtD
Amantadine—Alopecia—Sorafenib—thyroid cancer	0.0035	0.00508	CcSEcCtD
Amantadine—Mental disorder—Sorafenib—thyroid cancer	0.00347	0.00503	CcSEcCtD
Amantadine—Malnutrition—Sorafenib—thyroid cancer	0.00345	0.005	CcSEcCtD
Amantadine—Delirium—Epirubicin—thyroid cancer	0.00339	0.00491	CcSEcCtD
Amantadine—Body temperature increased—Vandetanib—thyroid cancer	0.0033	0.00478	CcSEcCtD
Amantadine—SIGMAR1—trachea—thyroid cancer	0.00327	0.0418	CbGeAlD
Amantadine—Delirium—Doxorubicin—thyroid cancer	0.00314	0.00455	CcSEcCtD
Amantadine—Dyskinesia—Epirubicin—thyroid cancer	0.0031	0.0045	CcSEcCtD
Amantadine—Leukopenia—Sorafenib—thyroid cancer	0.00309	0.00448	CcSEcCtD
Amantadine—Dysarthria—Epirubicin—thyroid cancer	0.00308	0.00447	CcSEcCtD
Amantadine—Asthenia—Vandetanib—thyroid cancer	0.00299	0.00434	CcSEcCtD
Amantadine—DDC—lymph node—thyroid cancer	0.00299	0.0382	CbGeAlD
Amantadine—Gait disturbance—Epirubicin—thyroid cancer	0.00299	0.00433	CcSEcCtD
Amantadine—Hypertension—Sorafenib—thyroid cancer	0.00298	0.00432	CcSEcCtD
Amantadine—Pruritus—Vandetanib—thyroid cancer	0.00295	0.00428	CcSEcCtD
Amantadine—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.00292	0.00423	CcSEcCtD
Amantadine—Dry mouth—Sorafenib—thyroid cancer	0.00287	0.00416	CcSEcCtD
Amantadine—Dyskinesia—Doxorubicin—thyroid cancer	0.00287	0.00416	CcSEcCtD
Amantadine—Diarrhoea—Vandetanib—thyroid cancer	0.00285	0.00414	CcSEcCtD
Amantadine—Dysarthria—Doxorubicin—thyroid cancer	0.00285	0.00414	CcSEcCtD
Amantadine—Anaphylactic shock—Sorafenib—thyroid cancer	0.00281	0.00408	CcSEcCtD
Amantadine—Gait disturbance—Doxorubicin—thyroid cancer	0.00276	0.00401	CcSEcCtD
Amantadine—Nervous system disorder—Sorafenib—thyroid cancer	0.00276	0.004	CcSEcCtD
Amantadine—Dizziness—Vandetanib—thyroid cancer	0.00276	0.004	CcSEcCtD
Amantadine—Skin disorder—Sorafenib—thyroid cancer	0.00273	0.00396	CcSEcCtD
Amantadine—Anorexia—Sorafenib—thyroid cancer	0.00268	0.00389	CcSEcCtD
Amantadine—Coma—Epirubicin—thyroid cancer	0.00266	0.00386	CcSEcCtD
Amantadine—Vomiting—Vandetanib—thyroid cancer	0.00265	0.00385	CcSEcCtD
Amantadine—Rash—Vandetanib—thyroid cancer	0.00263	0.00381	CcSEcCtD
Amantadine—Dermatitis—Vandetanib—thyroid cancer	0.00263	0.00381	CcSEcCtD
Amantadine—Headache—Vandetanib—thyroid cancer	0.00261	0.00379	CcSEcCtD
Amantadine—Pulmonary oedema—Epirubicin—thyroid cancer	0.0026	0.00376	CcSEcCtD
Amantadine—SIGMAR1—thyroid gland—thyroid cancer	0.00259	0.0331	CbGeAlD
Amantadine—Hypertonia—Epirubicin—thyroid cancer	0.00256	0.00371	CcSEcCtD
Amantadine—Mental disability—Epirubicin—thyroid cancer	0.00253	0.00367	CcSEcCtD
Amantadine—Dyspnoea—Sorafenib—thyroid cancer	0.00251	0.00364	CcSEcCtD
Amantadine—SLC22A1—head—thyroid cancer	0.00249	0.0317	CbGeAlD
Amantadine—Nausea—Vandetanib—thyroid cancer	0.00248	0.00359	CcSEcCtD
Amantadine—MAOB—thyroid gland—thyroid cancer	0.00248	0.0316	CbGeAlD
Amantadine—Dyspepsia—Sorafenib—thyroid cancer	0.00248	0.00359	CcSEcCtD
Amantadine—Coma—Doxorubicin—thyroid cancer	0.00246	0.00357	CcSEcCtD
Amantadine—Decreased appetite—Sorafenib—thyroid cancer	0.00245	0.00355	CcSEcCtD
Amantadine—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.00243	0.00352	CcSEcCtD
Amantadine—Fatigue—Sorafenib—thyroid cancer	0.00243	0.00352	CcSEcCtD
Amantadine—Photosensitivity—Epirubicin—thyroid cancer	0.00241	0.00349	CcSEcCtD
Amantadine—Constipation—Sorafenib—thyroid cancer	0.00241	0.00349	CcSEcCtD
Amantadine—Pulmonary oedema—Doxorubicin—thyroid cancer	0.0024	0.00348	CcSEcCtD
Amantadine—Hypertonia—Doxorubicin—thyroid cancer	0.00236	0.00343	CcSEcCtD
Amantadine—Eczema—Epirubicin—thyroid cancer	0.00235	0.00341	CcSEcCtD
Amantadine—Mental disability—Doxorubicin—thyroid cancer	0.00234	0.00339	CcSEcCtD
Amantadine—Cardiac failure congestive—Epirubicin—thyroid cancer	0.00233	0.00338	CcSEcCtD
Amantadine—Renal failure acute—Epirubicin—thyroid cancer	0.00229	0.00332	CcSEcCtD
Amantadine—Photosensitivity—Doxorubicin—thyroid cancer	0.00223	0.00323	CcSEcCtD
Amantadine—Body temperature increased—Sorafenib—thyroid cancer	0.00222	0.00323	CcSEcCtD
Amantadine—MAOB—head—thyroid cancer	0.0022	0.0281	CbGeAlD
Amantadine—Eczema—Doxorubicin—thyroid cancer	0.00218	0.00316	CcSEcCtD
Amantadine—Cardiac failure—Epirubicin—thyroid cancer	0.00217	0.00314	CcSEcCtD
Amantadine—Lethargy—Epirubicin—thyroid cancer	0.00216	0.00313	CcSEcCtD
Amantadine—Cardiac failure congestive—Doxorubicin—thyroid cancer	0.00216	0.00313	CcSEcCtD
Amantadine—Renal failure acute—Doxorubicin—thyroid cancer	0.00212	0.00308	CcSEcCtD
Amantadine—Osteoarthritis—Epirubicin—thyroid cancer	0.00212	0.00307	CcSEcCtD
Amantadine—Hypersensitivity—Sorafenib—thyroid cancer	0.00207	0.00301	CcSEcCtD
Amantadine—Asthenia—Sorafenib—thyroid cancer	0.00202	0.00293	CcSEcCtD
Amantadine—Cardiac arrest—Epirubicin—thyroid cancer	0.00201	0.00292	CcSEcCtD
Amantadine—Cardiac failure—Doxorubicin—thyroid cancer	0.00201	0.00291	CcSEcCtD
Amantadine—Lethargy—Doxorubicin—thyroid cancer	0.002	0.0029	CcSEcCtD
Amantadine—Pruritus—Sorafenib—thyroid cancer	0.00199	0.00289	CcSEcCtD
Amantadine—Ataxia—Epirubicin—thyroid cancer	0.00199	0.00289	CcSEcCtD
Amantadine—Osteoarthritis—Doxorubicin—thyroid cancer	0.00196	0.00284	CcSEcCtD
Amantadine—Liver function test abnormal—Epirubicin—thyroid cancer	0.00195	0.00283	CcSEcCtD
Amantadine—GRIN2D—CREB phosphorylation through the activation of Ras—HRAS—thyroid cancer	0.00194	0.00835	CbGpPWpGaD
Amantadine—Orthostatic hypotension—Epirubicin—thyroid cancer	0.00193	0.0028	CcSEcCtD
Amantadine—Diarrhoea—Sorafenib—thyroid cancer	0.00193	0.00279	CcSEcCtD
Amantadine—GRIN2B—Ras activation uopn Ca2+ infux through NMDA receptor—HRAS—thyroid cancer	0.0019	0.00817	CbGpPWpGaD
Amantadine—Cardiac arrest—Doxorubicin—thyroid cancer	0.00186	0.0027	CcSEcCtD
Amantadine—Dizziness—Sorafenib—thyroid cancer	0.00186	0.0027	CcSEcCtD
Amantadine—DRD2—head—thyroid cancer	0.00185	0.0237	CbGeAlD
Amantadine—Ataxia—Doxorubicin—thyroid cancer	0.00184	0.00267	CcSEcCtD
Amantadine—DDC—SIDS Susceptibility Pathways—SST—thyroid cancer	0.00184	0.00792	CbGpPWpGaD
Amantadine—Dysphagia—Epirubicin—thyroid cancer	0.00183	0.00265	CcSEcCtD
Amantadine—Liver function test abnormal—Doxorubicin—thyroid cancer	0.00181	0.00262	CcSEcCtD
Amantadine—Vomiting—Sorafenib—thyroid cancer	0.00179	0.00259	CcSEcCtD
Amantadine—Orthostatic hypotension—Doxorubicin—thyroid cancer	0.00179	0.00259	CcSEcCtD
Amantadine—Rash—Sorafenib—thyroid cancer	0.00177	0.00257	CcSEcCtD
Amantadine—Dermatitis—Sorafenib—thyroid cancer	0.00177	0.00257	CcSEcCtD
Amantadine—Headache—Sorafenib—thyroid cancer	0.00176	0.00256	CcSEcCtD
Amantadine—GRIN1—Spinal Cord Injury—CDK1—thyroid cancer	0.00172	0.00741	CbGpPWpGaD
Amantadine—GRIN2C—Post NMDA receptor activation events—HRAS—thyroid cancer	0.00171	0.00739	CbGpPWpGaD
Amantadine—Neutropenia—Epirubicin—thyroid cancer	0.00171	0.00248	CcSEcCtD
Amantadine—Dysphagia—Doxorubicin—thyroid cancer	0.00169	0.00245	CcSEcCtD
Amantadine—Nausea—Sorafenib—thyroid cancer	0.00167	0.00242	CcSEcCtD
Amantadine—Photosensitivity reaction—Epirubicin—thyroid cancer	0.00167	0.00242	CcSEcCtD
Amantadine—SIGMAR1—lymph node—thyroid cancer	0.00161	0.0205	CbGeAlD
Amantadine—GRIN2D—Post NMDA receptor activation events—HRAS—thyroid cancer	0.00159	0.00687	CbGpPWpGaD
Amantadine—GRIN2A—CREB phosphorylation through the activation of Ras—HRAS—thyroid cancer	0.00159	0.00685	CbGpPWpGaD
Amantadine—Neutropenia—Doxorubicin—thyroid cancer	0.00158	0.00229	CcSEcCtD
Amantadine—GRIN2C—Activation of NMDA receptor upon glutamate binding and postsynaptic events—HRAS—thyroid cancer	0.00158	0.00681	CbGpPWpGaD
Amantadine—GRIN1—SIDS Susceptibility Pathways—SST—thyroid cancer	0.00158	0.00681	CbGpPWpGaD
Amantadine—Photosensitivity reaction—Doxorubicin—thyroid cancer	0.00154	0.00224	CcSEcCtD
Amantadine—SLC22A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—CP—thyroid cancer	0.00154	0.00665	CbGpPWpGaD
Amantadine—MAOB—lymph node—thyroid cancer	0.00154	0.0197	CbGeAlD
Amantadine—DDC—Amino acid and derivative metabolism—SLC5A5—thyroid cancer	0.00152	0.00657	CbGpPWpGaD
Amantadine—Agranulocytosis—Epirubicin—thyroid cancer	0.00152	0.00221	CcSEcCtD
Amantadine—GRIN2D—Activation of NMDA receptor upon glutamate binding and postsynaptic events—HRAS—thyroid cancer	0.00147	0.00633	CbGpPWpGaD
Amantadine—Urinary tract disorder—Epirubicin—thyroid cancer	0.00145	0.0021	CcSEcCtD
Amantadine—GRIN2A—Reelin signaling pathway—AKT1—thyroid cancer	0.00144	0.00622	CbGpPWpGaD
Amantadine—Oedema peripheral—Epirubicin—thyroid cancer	0.00144	0.00209	CcSEcCtD
Amantadine—SLC22A1—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—CP—thyroid cancer	0.00144	0.0062	CbGpPWpGaD
Amantadine—Urethral disorder—Epirubicin—thyroid cancer	0.00144	0.00208	CcSEcCtD
Amantadine—Visual impairment—Epirubicin—thyroid cancer	0.00141	0.00205	CcSEcCtD
Amantadine—Agranulocytosis—Doxorubicin—thyroid cancer	0.00141	0.00204	CcSEcCtD
Amantadine—GRIN1—CREB phosphorylation through the activation of Ras—HRAS—thyroid cancer	0.00139	0.00598	CbGpPWpGaD
Amantadine—Eye disorder—Epirubicin—thyroid cancer	0.00137	0.00198	CcSEcCtD
Amantadine—Cardiac disorder—Epirubicin—thyroid cancer	0.00136	0.00197	CcSEcCtD
Amantadine—GRIN2B—CREB phosphorylation through the activation of Ras—HRAS—thyroid cancer	0.00135	0.00583	CbGpPWpGaD
Amantadine—Urinary tract disorder—Doxorubicin—thyroid cancer	0.00134	0.00194	CcSEcCtD
Amantadine—Oedema peripheral—Doxorubicin—thyroid cancer	0.00133	0.00193	CcSEcCtD
Amantadine—Angiopathy—Epirubicin—thyroid cancer	0.00133	0.00193	CcSEcCtD
Amantadine—Urethral disorder—Doxorubicin—thyroid cancer	0.00133	0.00193	CcSEcCtD
Amantadine—Mediastinal disorder—Epirubicin—thyroid cancer	0.00132	0.00191	CcSEcCtD
Amantadine—GRIN2A—Post NMDA receptor activation events—HRAS—thyroid cancer	0.00131	0.00564	CbGpPWpGaD
Amantadine—Arrhythmia—Epirubicin—thyroid cancer	0.00131	0.0019	CcSEcCtD
Amantadine—Visual impairment—Doxorubicin—thyroid cancer	0.00131	0.00189	CcSEcCtD
Amantadine—Alopecia—Epirubicin—thyroid cancer	0.00129	0.00188	CcSEcCtD
Amantadine—ABCB1—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.00129	0.00555	CbGpPWpGaD
Amantadine—GRIN2C—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—thyroid cancer	0.00129	0.00554	CbGpPWpGaD
Amantadine—Mental disorder—Epirubicin—thyroid cancer	0.00128	0.00186	CcSEcCtD
Amantadine—Malnutrition—Epirubicin—thyroid cancer	0.00127	0.00185	CcSEcCtD
Amantadine—Eye disorder—Doxorubicin—thyroid cancer	0.00127	0.00184	CcSEcCtD
Amantadine—Cardiac disorder—Doxorubicin—thyroid cancer	0.00126	0.00182	CcSEcCtD
Amantadine—Tension—Epirubicin—thyroid cancer	0.00125	0.00181	CcSEcCtD
Amantadine—Nervousness—Epirubicin—thyroid cancer	0.00124	0.00179	CcSEcCtD
Amantadine—Angiopathy—Doxorubicin—thyroid cancer	0.00123	0.00178	CcSEcCtD
Amantadine—GRIN2B—Reelin signaling pathway—AKT1—thyroid cancer	0.00123	0.00529	CbGpPWpGaD
Amantadine—Mediastinal disorder—Doxorubicin—thyroid cancer	0.00122	0.00177	CcSEcCtD
Amantadine—Arrhythmia—Doxorubicin—thyroid cancer	0.00121	0.00175	CcSEcCtD
Amantadine—GRIN2A—Activation of NMDA receptor upon glutamate binding and postsynaptic events—HRAS—thyroid cancer	0.00121	0.0052	CbGpPWpGaD
Amantadine—Vision blurred—Epirubicin—thyroid cancer	0.0012	0.00174	CcSEcCtD
Amantadine—Alopecia—Doxorubicin—thyroid cancer	0.0012	0.00174	CcSEcCtD
Amantadine—GRIN2D—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—thyroid cancer	0.0012	0.00515	CbGpPWpGaD
Amantadine—Mental disorder—Doxorubicin—thyroid cancer	0.00119	0.00172	CcSEcCtD
Amantadine—DRD2—Circadian rythm related genes—NKX2-1—thyroid cancer	0.00118	0.00509	CbGpPWpGaD
Amantadine—Malnutrition—Doxorubicin—thyroid cancer	0.00118	0.00171	CcSEcCtD
Amantadine—Agitation—Epirubicin—thyroid cancer	0.00117	0.0017	CcSEcCtD
Amantadine—Tension—Doxorubicin—thyroid cancer	0.00116	0.00168	CcSEcCtD
Amantadine—MAOB—Biological oxidations—RXRA—thyroid cancer	0.00116	0.00499	CbGpPWpGaD
Amantadine—ABCB1—HIF-1-alpha transcription factor network—CP—thyroid cancer	0.00115	0.00495	CbGpPWpGaD
Amantadine—Nervousness—Doxorubicin—thyroid cancer	0.00115	0.00166	CcSEcCtD
Amantadine—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—EPO—thyroid cancer	0.00114	0.00493	CbGpPWpGaD
Amantadine—ABCB1—trachea—thyroid cancer	0.00114	0.0146	CbGeAlD
Amantadine—GRIN1—Post NMDA receptor activation events—HRAS—thyroid cancer	0.00114	0.00492	CbGpPWpGaD
Amantadine—Leukopenia—Epirubicin—thyroid cancer	0.00114	0.00165	CcSEcCtD
Amantadine—Palpitations—Epirubicin—thyroid cancer	0.00113	0.00163	CcSEcCtD
Amantadine—GRIN2B—Post NMDA receptor activation events—HRAS—thyroid cancer	0.00111	0.0048	CbGpPWpGaD
Amantadine—Vision blurred—Doxorubicin—thyroid cancer	0.00111	0.00161	CcSEcCtD
Amantadine—Convulsion—Epirubicin—thyroid cancer	0.0011	0.0016	CcSEcCtD
Amantadine—DDC—SIDS Susceptibility Pathways—HIF1A—thyroid cancer	0.0011	0.00476	CbGpPWpGaD
Amantadine—Hypertension—Epirubicin—thyroid cancer	0.0011	0.0016	CcSEcCtD
Amantadine—Agitation—Doxorubicin—thyroid cancer	0.00108	0.00157	CcSEcCtD
Amantadine—Anxiety—Epirubicin—thyroid cancer	0.00108	0.00157	CcSEcCtD
Amantadine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.00108	0.00156	CcSEcCtD
Amantadine—Dry mouth—Epirubicin—thyroid cancer	0.00106	0.00154	CcSEcCtD
Amantadine—Leukopenia—Doxorubicin—thyroid cancer	0.00106	0.00153	CcSEcCtD
Amantadine—GRIN1—EPHB-mediated forward signaling—HRAS—thyroid cancer	0.00105	0.00453	CbGpPWpGaD
Amantadine—GRIN1—Activation of NMDA receptor upon glutamate binding and postsynaptic events—HRAS—thyroid cancer	0.00105	0.00453	CbGpPWpGaD
Amantadine—Confusional state—Epirubicin—thyroid cancer	0.00105	0.00152	CcSEcCtD
Amantadine—Palpitations—Doxorubicin—thyroid cancer	0.00104	0.00151	CcSEcCtD
Amantadine—Oedema—Epirubicin—thyroid cancer	0.00104	0.00151	CcSEcCtD
Amantadine—Anaphylactic shock—Epirubicin—thyroid cancer	0.00104	0.00151	CcSEcCtD
Amantadine—GRIN2B—EPHB-mediated forward signaling—HRAS—thyroid cancer	0.00102	0.00442	CbGpPWpGaD
Amantadine—GRIN2B—Activation of NMDA receptor upon glutamate binding and postsynaptic events—HRAS—thyroid cancer	0.00102	0.00442	CbGpPWpGaD
Amantadine—Convulsion—Doxorubicin—thyroid cancer	0.00102	0.00148	CcSEcCtD
Amantadine—Nervous system disorder—Epirubicin—thyroid cancer	0.00102	0.00148	CcSEcCtD
Amantadine—Hypertension—Doxorubicin—thyroid cancer	0.00102	0.00148	CcSEcCtD
Amantadine—Tachycardia—Epirubicin—thyroid cancer	0.00102	0.00147	CcSEcCtD
Amantadine—Skin disorder—Epirubicin—thyroid cancer	0.00101	0.00146	CcSEcCtD
Amantadine—DDC—Metabolism—MINPP1—thyroid cancer	0.00101	0.00435	CbGpPWpGaD
Amantadine—Hyperhidrosis—Epirubicin—thyroid cancer	0.00101	0.00146	CcSEcCtD
Amantadine—Anxiety—Doxorubicin—thyroid cancer	0.001	0.00145	CcSEcCtD
Amantadine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.000997	0.00145	CcSEcCtD
Amantadine—Anorexia—Epirubicin—thyroid cancer	0.000992	0.00144	CcSEcCtD
Amantadine—Dry mouth—Doxorubicin—thyroid cancer	0.000982	0.00142	CcSEcCtD
Amantadine—GRIN2A—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—thyroid cancer	0.000981	0.00423	CbGpPWpGaD
Amantadine—GRIN2C—Alzheimers Disease—TP53—thyroid cancer	0.000977	0.00421	CbGpPWpGaD
Amantadine—Hypotension—Epirubicin—thyroid cancer	0.000972	0.00141	CcSEcCtD
Amantadine—Confusional state—Doxorubicin—thyroid cancer	0.00097	0.00141	CcSEcCtD
Amantadine—GRIN2C—Transmission across Chemical Synapses—BRAF—thyroid cancer	0.000966	0.00417	CbGpPWpGaD
Amantadine—Oedema—Doxorubicin—thyroid cancer	0.000962	0.0014	CcSEcCtD
Amantadine—Anaphylactic shock—Doxorubicin—thyroid cancer	0.000962	0.0014	CcSEcCtD
Amantadine—GRIN1—SIDS Susceptibility Pathways—HIF1A—thyroid cancer	0.000948	0.00409	CbGpPWpGaD
Amantadine—Nervous system disorder—Doxorubicin—thyroid cancer	0.000944	0.00137	CcSEcCtD
Amantadine—Insomnia—Epirubicin—thyroid cancer	0.000941	0.00136	CcSEcCtD
Amantadine—Tachycardia—Doxorubicin—thyroid cancer	0.000939	0.00136	CcSEcCtD
Amantadine—Skin disorder—Doxorubicin—thyroid cancer	0.000935	0.00136	CcSEcCtD
Amantadine—Paraesthesia—Epirubicin—thyroid cancer	0.000934	0.00135	CcSEcCtD
Amantadine—Hyperhidrosis—Doxorubicin—thyroid cancer	0.00093	0.00135	CcSEcCtD
Amantadine—Dyspnoea—Epirubicin—thyroid cancer	0.000927	0.00134	CcSEcCtD
Amantadine—Somnolence—Epirubicin—thyroid cancer	0.000925	0.00134	CcSEcCtD
Amantadine—Anorexia—Doxorubicin—thyroid cancer	0.000917	0.00133	CcSEcCtD
Amantadine—Dyspepsia—Epirubicin—thyroid cancer	0.000916	0.00133	CcSEcCtD
Amantadine—GRIN2D—Alzheimers Disease—TP53—thyroid cancer	0.000908	0.00391	CbGpPWpGaD
Amantadine—Decreased appetite—Epirubicin—thyroid cancer	0.000904	0.00131	CcSEcCtD
Amantadine—ABCB1—thyroid gland—thyroid cancer	0.000904	0.0115	CbGeAlD
Amantadine—ABCB1—HIF-1-alpha transcription factor network—EPO—thyroid cancer	0.0009	0.00388	CbGpPWpGaD
Amantadine—Hypotension—Doxorubicin—thyroid cancer	0.000899	0.0013	CcSEcCtD
Amantadine—GRIN2D—Transmission across Chemical Synapses—BRAF—thyroid cancer	0.000898	0.00387	CbGpPWpGaD
Amantadine—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.000898	0.0013	CcSEcCtD
Amantadine—Fatigue—Epirubicin—thyroid cancer	0.000897	0.0013	CcSEcCtD
Amantadine—Constipation—Epirubicin—thyroid cancer	0.000889	0.00129	CcSEcCtD
Amantadine—DRD2—GPCR ligand binding—CALCB—thyroid cancer	0.000878	0.00378	CbGpPWpGaD
Amantadine—Insomnia—Doxorubicin—thyroid cancer	0.00087	0.00126	CcSEcCtD
Amantadine—Paraesthesia—Doxorubicin—thyroid cancer	0.000864	0.00125	CcSEcCtD
Amantadine—DDC—Metabolism—NDUFA13—thyroid cancer	0.000858	0.0037	CbGpPWpGaD
Amantadine—Dyspnoea—Doxorubicin—thyroid cancer	0.000858	0.00124	CcSEcCtD
Amantadine—Feeling abnormal—Epirubicin—thyroid cancer	0.000857	0.00124	CcSEcCtD
Amantadine—GRIN1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—thyroid cancer	0.000856	0.00369	CbGpPWpGaD
Amantadine—Somnolence—Doxorubicin—thyroid cancer	0.000856	0.00124	CcSEcCtD
Amantadine—MAOB—Metabolism—MINPP1—thyroid cancer	0.00085	0.00366	CbGpPWpGaD
Amantadine—Dyspepsia—Doxorubicin—thyroid cancer	0.000847	0.00123	CcSEcCtD
Amantadine—Decreased appetite—Doxorubicin—thyroid cancer	0.000837	0.00121	CcSEcCtD
Amantadine—GRIN2B—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—thyroid cancer	0.000834	0.0036	CbGpPWpGaD
Amantadine—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.000831	0.0012	CcSEcCtD
Amantadine—Fatigue—Doxorubicin—thyroid cancer	0.00083	0.0012	CcSEcCtD
Amantadine—Constipation—Doxorubicin—thyroid cancer	0.000823	0.00119	CcSEcCtD
Amantadine—Body temperature increased—Epirubicin—thyroid cancer	0.000822	0.00119	CcSEcCtD
Amantadine—DDC—Metabolism—CHST14—thyroid cancer	0.000807	0.00348	CbGpPWpGaD
Amantadine—ABCB1—head—thyroid cancer	0.000802	0.0102	CbGeAlD
Amantadine—Feeling abnormal—Doxorubicin—thyroid cancer	0.000793	0.00115	CcSEcCtD
Amantadine—GRIN1—Spinal Cord Injury—PTGS2—thyroid cancer	0.000793	0.00342	CbGpPWpGaD
Amantadine—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.000775	0.00334	CbGpPWpGaD
Amantadine—GRIN1—Axon guidance—CDK1—thyroid cancer	0.000766	0.0033	CbGpPWpGaD
Amantadine—Hypersensitivity—Epirubicin—thyroid cancer	0.000766	0.00111	CcSEcCtD
Amantadine—DDC—Circadian rythm related genes—PPARG—thyroid cancer	0.000766	0.0033	CbGpPWpGaD
Amantadine—Body temperature increased—Doxorubicin—thyroid cancer	0.000761	0.0011	CcSEcCtD
Amantadine—GRIN2B—Axon guidance—CDK1—thyroid cancer	0.000747	0.00322	CbGpPWpGaD
Amantadine—Asthenia—Epirubicin—thyroid cancer	0.000746	0.00108	CcSEcCtD
Amantadine—GRIN2A—Alzheimers Disease—TP53—thyroid cancer	0.000746	0.00321	CbGpPWpGaD
Amantadine—GRIN2C—Neuronal System—BRAF—thyroid cancer	0.00074	0.00319	CbGpPWpGaD
Amantadine—GRIN2A—Transmission across Chemical Synapses—BRAF—thyroid cancer	0.000738	0.00318	CbGpPWpGaD
Amantadine—Pruritus—Epirubicin—thyroid cancer	0.000736	0.00107	CcSEcCtD
Amantadine—MAOB—Metabolism—NDUFA13—thyroid cancer	0.000723	0.00312	CbGpPWpGaD
Amantadine—GRIN1—Spinal Cord Injury—CCND1—thyroid cancer	0.000716	0.00309	CbGpPWpGaD
Amantadine—Diarrhoea—Epirubicin—thyroid cancer	0.000712	0.00103	CcSEcCtD
Amantadine—Hypersensitivity—Doxorubicin—thyroid cancer	0.000709	0.00103	CcSEcCtD
Amantadine—SLC22A2—SLC-mediated transmembrane transport—TPR—thyroid cancer	0.000701	0.00302	CbGpPWpGaD
Amantadine—SLC22A2—SLC-mediated transmembrane transport—CP—thyroid cancer	0.000701	0.00302	CbGpPWpGaD
Amantadine—Asthenia—Doxorubicin—thyroid cancer	0.000691	0.001	CcSEcCtD
Amantadine—GRIN2D—Neuronal System—BRAF—thyroid cancer	0.000688	0.00297	CbGpPWpGaD
Amantadine—Dizziness—Epirubicin—thyroid cancer	0.000688	0.000997	CcSEcCtD
Amantadine—Pruritus—Doxorubicin—thyroid cancer	0.000681	0.000987	CcSEcCtD
Amantadine—MAOB—Metabolism—CHST14—thyroid cancer	0.000679	0.00293	CbGpPWpGaD
Amantadine—Vomiting—Epirubicin—thyroid cancer	0.000661	0.000959	CcSEcCtD
Amantadine—Diarrhoea—Doxorubicin—thyroid cancer	0.000659	0.000955	CcSEcCtD
Amantadine—Rash—Epirubicin—thyroid cancer	0.000656	0.000951	CcSEcCtD
Amantadine—Dermatitis—Epirubicin—thyroid cancer	0.000655	0.00095	CcSEcCtD
Amantadine—SLC22A1—SLC-mediated transmembrane transport—CP—thyroid cancer	0.000654	0.00282	CbGpPWpGaD
Amantadine—SLC22A1—SLC-mediated transmembrane transport—TPR—thyroid cancer	0.000654	0.00282	CbGpPWpGaD
Amantadine—Headache—Epirubicin—thyroid cancer	0.000652	0.000945	CcSEcCtD
Amantadine—DDC—Metabolism—HPGD—thyroid cancer	0.000651	0.0028	CbGpPWpGaD
Amantadine—GRIN1—Alzheimers Disease—TP53—thyroid cancer	0.00065	0.0028	CbGpPWpGaD
Amantadine—GRIN1—Transmission across Chemical Synapses—BRAF—thyroid cancer	0.000644	0.00277	CbGpPWpGaD
Amantadine—Dizziness—Doxorubicin—thyroid cancer	0.000636	0.000923	CcSEcCtD
Amantadine—GRIN2B—Alzheimers Disease—TP53—thyroid cancer	0.000634	0.00273	CbGpPWpGaD
Amantadine—GRIN2B—Transmission across Chemical Synapses—BRAF—thyroid cancer	0.000627	0.0027	CbGpPWpGaD
Amantadine—Nausea—Epirubicin—thyroid cancer	0.000618	0.000896	CcSEcCtD
Amantadine—Vomiting—Doxorubicin—thyroid cancer	0.000612	0.000887	CcSEcCtD
Amantadine—Rash—Doxorubicin—thyroid cancer	0.000607	0.00088	CcSEcCtD
Amantadine—Dermatitis—Doxorubicin—thyroid cancer	0.000606	0.000879	CcSEcCtD
Amantadine—Headache—Doxorubicin—thyroid cancer	0.000603	0.000874	CcSEcCtD
Amantadine—GRIN2C—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—thyroid cancer	0.000591	0.00255	CbGpPWpGaD
Amantadine—Nausea—Doxorubicin—thyroid cancer	0.000572	0.000829	CcSEcCtD
Amantadine—GRIN2A—Neuronal System—BRAF—thyroid cancer	0.000565	0.00244	CbGpPWpGaD
Amantadine—ABCB1—lymph node—thyroid cancer	0.000561	0.00717	CbGeAlD
Amantadine—ABCB1—HIF-1-alpha transcription factor network—TERT—thyroid cancer	0.00056	0.00242	CbGpPWpGaD
Amantadine—GRIN2D—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—thyroid cancer	0.000549	0.00237	CbGpPWpGaD
Amantadine—MAOB—Metabolism—HPGD—thyroid cancer	0.000548	0.00236	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—CDK1—thyroid cancer	0.000547	0.00236	CbGpPWpGaD
Amantadine—GRIN1—EPH-Ephrin signaling—HRAS—thyroid cancer	0.000541	0.00233	CbGpPWpGaD
Amantadine—ABCB1—HIF-1-alpha transcription factor network—HIF1A—thyroid cancer	0.000536	0.00231	CbGpPWpGaD
Amantadine—DRD2—Class A/1 (Rhodopsin-like receptors)—TSHR—thyroid cancer	0.000534	0.0023	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—CDK1—thyroid cancer	0.000533	0.0023	CbGpPWpGaD
Amantadine—GRIN2B—EPH-Ephrin signaling—HRAS—thyroid cancer	0.000528	0.00227	CbGpPWpGaD
Amantadine—DDC—Circadian rythm related genes—PTEN—thyroid cancer	0.000526	0.00227	CbGpPWpGaD
Amantadine—SLC22A2—SLC-mediated transmembrane transport—SLC5A5—thyroid cancer	0.000525	0.00226	CbGpPWpGaD
Amantadine—DRD2—G alpha (i) signalling events—SST—thyroid cancer	0.000522	0.00225	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—RXRA—thyroid cancer	0.000508	0.00219	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—CALCB—thyroid cancer	0.000496	0.00214	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—RXRA—thyroid cancer	0.000495	0.00213	CbGpPWpGaD
Amantadine—GRIN1—Neuronal System—BRAF—thyroid cancer	0.000493	0.00213	CbGpPWpGaD
Amantadine—SLC22A1—SLC-mediated transmembrane transport—SLC5A5—thyroid cancer	0.000489	0.00211	CbGpPWpGaD
Amantadine—GRIN2B—Neuronal System—BRAF—thyroid cancer	0.000481	0.00207	CbGpPWpGaD
Amantadine—GRIN1—Spinal Cord Injury—TP53—thyroid cancer	0.000472	0.00203	CbGpPWpGaD
Amantadine—GRIN2A—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—thyroid cancer	0.000451	0.00195	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—MINPP1—thyroid cancer	0.000451	0.00194	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—CALCB—thyroid cancer	0.00045	0.00194	CbGpPWpGaD
Amantadine—GRIN2C—Transmission across Chemical Synapses—HRAS—thyroid cancer	0.000444	0.00192	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—MINPP1—thyroid cancer	0.00042	0.00181	CbGpPWpGaD
Amantadine—DRD2—Class A/1 (Rhodopsin-like receptors)—SST—thyroid cancer	0.000415	0.00179	CbGpPWpGaD
Amantadine—GRIN2D—Transmission across Chemical Synapses—HRAS—thyroid cancer	0.000413	0.00178	CbGpPWpGaD
Amantadine—DRD2—GPCR ligand binding—TSHR—thyroid cancer	0.000406	0.00175	CbGpPWpGaD
Amantadine—GRIN1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—thyroid cancer	0.000394	0.0017	CbGpPWpGaD
Amantadine—GRIN1—BDNF signaling pathway—HRAS—thyroid cancer	0.000385	0.00166	CbGpPWpGaD
Amantadine—GRIN2B—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—thyroid cancer	0.000384	0.00165	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—NDUFA13—thyroid cancer	0.000383	0.00165	CbGpPWpGaD
Amantadine—GRIN2B—BDNF signaling pathway—HRAS—thyroid cancer	0.000375	0.00162	CbGpPWpGaD
Amantadine—DDC—Metabolism—TPR—thyroid cancer	0.000374	0.00161	CbGpPWpGaD
Amantadine—DDC—Metabolism—PRKAR1A—thyroid cancer	0.000368	0.00158	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—CHST14—thyroid cancer	0.000361	0.00155	CbGpPWpGaD
Amantadine—DDC—Circadian rythm related genes—TP53—thyroid cancer	0.000359	0.00155	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—NDUFA13—thyroid cancer	0.000357	0.00154	CbGpPWpGaD
Amantadine—SLC22A2—Transmembrane transport of small molecules—TPR—thyroid cancer	0.000356	0.00154	CbGpPWpGaD
Amantadine—SLC22A2—Transmembrane transport of small molecules—CP—thyroid cancer	0.000356	0.00154	CbGpPWpGaD
Amantadine—SLC22A2—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	0.000351	0.00151	CbGpPWpGaD
Amantadine—DRD2—GPCR ligand binding—PTCH1—thyroid cancer	0.000345	0.00149	CbGpPWpGaD
Amantadine—GRIN2C—Neuronal System—HRAS—thyroid cancer	0.00034	0.00147	CbGpPWpGaD
Amantadine—GRIN1—BDNF signaling pathway—AKT1—thyroid cancer	0.00034	0.00146	CbGpPWpGaD
Amantadine—GRIN2A—Transmission across Chemical Synapses—HRAS—thyroid cancer	0.000339	0.00146	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—CHST14—thyroid cancer	0.000336	0.00145	CbGpPWpGaD
Amantadine—SLC22A2—Transmission across Chemical Synapses—BRAF—thyroid cancer	0.000335	0.00144	CbGpPWpGaD
Amantadine—SLC22A1—Transmembrane transport of small molecules—TPR—thyroid cancer	0.000332	0.00143	CbGpPWpGaD
Amantadine—SLC22A1—Transmembrane transport of small molecules—CP—thyroid cancer	0.000332	0.00143	CbGpPWpGaD
Amantadine—GRIN2B—BDNF signaling pathway—AKT1—thyroid cancer	0.000331	0.00143	CbGpPWpGaD
Amantadine—SLC22A1—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	0.000327	0.00141	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—PPARG—thyroid cancer	0.000321	0.00138	CbGpPWpGaD
Amantadine—GRIN2D—Neuronal System—HRAS—thyroid cancer	0.000316	0.00136	CbGpPWpGaD
Amantadine—DRD2—GPCR ligand binding—SST—thyroid cancer	0.000316	0.00136	CbGpPWpGaD
Amantadine—MAOB—Metabolism—TPR—thyroid cancer	0.000315	0.00136	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—PPARG—thyroid cancer	0.000312	0.00135	CbGpPWpGaD
Amantadine—SLC22A1—Transmission across Chemical Synapses—BRAF—thyroid cancer	0.000312	0.00134	CbGpPWpGaD
Amantadine—MAOB—Metabolism—PRKAR1A—thyroid cancer	0.000309	0.00133	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—RXRA—thyroid cancer	0.000308	0.00133	CbGpPWpGaD
Amantadine—DRD2—GPCR ligand binding—CALCA—thyroid cancer	0.000304	0.00131	CbGpPWpGaD
Amantadine—DRD2—Circadian rythm related genes—PPARG—thyroid cancer	0.000302	0.0013	CbGpPWpGaD
Amantadine—GRIN1—Transmission across Chemical Synapses—HRAS—thyroid cancer	0.000296	0.00128	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—HPGD—thyroid cancer	0.000291	0.00125	CbGpPWpGaD
Amantadine—GRIN2B—Transmission across Chemical Synapses—HRAS—thyroid cancer	0.000288	0.00124	CbGpPWpGaD
Amantadine—DDC—Metabolism—SLC5A5—thyroid cancer	0.00028	0.00121	CbGpPWpGaD
Amantadine—GRIN1—Axon guidance—NRAS—thyroid cancer	0.000275	0.00119	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—HPGD—thyroid cancer	0.000271	0.00117	CbGpPWpGaD
Amantadine—GRIN2B—Axon guidance—NRAS—thyroid cancer	0.000268	0.00116	CbGpPWpGaD
Amantadine—SLC22A2—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	0.000267	0.00115	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CALCB—thyroid cancer	0.000266	0.00115	CbGpPWpGaD
Amantadine—GRIN2A—Neuronal System—HRAS—thyroid cancer	0.00026	0.00112	CbGpPWpGaD
Amantadine—SLC22A2—Neuronal System—BRAF—thyroid cancer	0.000256	0.00111	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—TRIM33—thyroid cancer	0.000252	0.00109	CbGpPWpGaD
Amantadine—SLC22A1—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	0.000249	0.00107	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—MINPP1—thyroid cancer	0.000246	0.00106	CbGpPWpGaD
Amantadine—SLC22A1—Neuronal System—BRAF—thyroid cancer	0.000239	0.00103	CbGpPWpGaD
Amantadine—GRIN1—Axon guidance—KRAS—thyroid cancer	0.000237	0.00102	CbGpPWpGaD
Amantadine—MAOB—Metabolism—SLC5A5—thyroid cancer	0.000235	0.00102	CbGpPWpGaD
Amantadine—DDC—Metabolism—RXRA—thyroid cancer	0.000235	0.00101	CbGpPWpGaD
Amantadine—GRIN2B—Axon guidance—KRAS—thyroid cancer	0.000231	0.000994	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—TSHR—thyroid cancer	0.00023	0.00099	CbGpPWpGaD
Amantadine—GRIN1—Neuronal System—HRAS—thyroid cancer	0.000227	0.000977	CbGpPWpGaD
Amantadine—SLC22A2—Transmembrane transport of small molecules—RXRA—thyroid cancer	0.000224	0.000966	CbGpPWpGaD
Amantadine—GRIN2B—Neuronal System—HRAS—thyroid cancer	0.000221	0.000953	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—NDUFA13—thyroid cancer	0.000209	0.000903	CbGpPWpGaD
Amantadine—SLC22A1—Transmembrane transport of small molecules—RXRA—thyroid cancer	0.000209	0.000901	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—TSHR—thyroid cancer	0.000209	0.000899	CbGpPWpGaD
Amantadine—DRD2—Circadian rythm related genes—PTEN—thyroid cancer	0.000207	0.000893	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—PRKAR1A—thyroid cancer	0.000205	0.000884	CbGpPWpGaD
Amantadine—GRIN1—Axon guidance—HRAS—thyroid cancer	0.000201	0.000867	CbGpPWpGaD
Amantadine—MAOB—Metabolism—RXRA—thyroid cancer	0.000198	0.000853	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—CHST14—thyroid cancer	0.000197	0.000849	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—NRAS—thyroid cancer	0.000196	0.000846	CbGpPWpGaD
Amantadine—GRIN2B—Axon guidance—HRAS—thyroid cancer	0.000196	0.000845	CbGpPWpGaD
Amantadine—ABCB1—Transmembrane transport of small molecules—CP—thyroid cancer	0.000195	0.000839	CbGpPWpGaD
Amantadine—ABCB1—Transmembrane transport of small molecules—TPR—thyroid cancer	0.000195	0.000839	CbGpPWpGaD
Amantadine—ABCB1—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	0.000192	0.000826	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—NRAS—thyroid cancer	0.000191	0.000825	CbGpPWpGaD
Amantadine—ABCB1—HIF-1-alpha transcription factor network—AKT1—thyroid cancer	0.00018	0.000777	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—SST—thyroid cancer	0.000179	0.00077	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—PTCH1—thyroid cancer	0.000177	0.000764	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—CALCA—thyroid cancer	0.000172	0.000741	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—KRAS—thyroid cancer	0.000169	0.000728	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—TCF7L1—thyroid cancer	0.000168	0.000725	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—TPR—thyroid cancer	0.000167	0.00072	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—KRAS—thyroid cancer	0.000165	0.00071	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—PRKAR1A—thyroid cancer	0.000164	0.000708	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—SST—thyroid cancer	0.000162	0.000699	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—HPGD—thyroid cancer	0.000159	0.000684	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—CALCA—thyroid cancer	0.000156	0.000673	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—TPR—thyroid cancer	0.000156	0.000671	CbGpPWpGaD
Amantadine—SLC22A2—Transmission across Chemical Synapses—HRAS—thyroid cancer	0.000154	0.000663	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—thyroid cancer	0.000153	0.00066	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—PRKAR1A—thyroid cancer	0.000153	0.00066	CbGpPWpGaD
Amantadine—DDC—Metabolism—PPARG—thyroid cancer	0.000148	0.00064	CbGpPWpGaD
Amantadine—ABCB1—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	0.000146	0.000628	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—HRAS—thyroid cancer	0.000144	0.000619	CbGpPWpGaD
Amantadine—SLC22A1—Transmission across Chemical Synapses—HRAS—thyroid cancer	0.000143	0.000618	CbGpPWpGaD
Amantadine—DRD2—Circadian rythm related genes—TP53—thyroid cancer	0.000141	0.00061	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—CDK1—thyroid cancer	0.000141	0.000609	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—HRAS—thyroid cancer	0.00014	0.000603	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—thyroid cancer	0.000138	0.000597	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—thyroid cancer	0.000134	0.000576	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—AKT1—thyroid cancer	0.000127	0.000546	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—SLC5A5—thyroid cancer	0.000125	0.000539	CbGpPWpGaD
Amantadine—MAOB—Metabolism—PPARG—thyroid cancer	0.000125	0.000538	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—AKT1—thyroid cancer	0.000124	0.000533	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—TSHR—thyroid cancer	0.000123	0.000531	CbGpPWpGaD
Amantadine—ABCB1—Transmembrane transport of small molecules—RXRA—thyroid cancer	0.000122	0.000528	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—PRKAR1A—thyroid cancer	0.000121	0.000522	CbGpPWpGaD
Amantadine—SLC22A2—Neuronal System—HRAS—thyroid cancer	0.000118	0.000508	CbGpPWpGaD
Amantadine—DDC—Metabolism—PTGS2—thyroid cancer	0.000117	0.000503	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—SLC5A5—thyroid cancer	0.000116	0.000502	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—MEN1—thyroid cancer	0.000116	0.000499	CbGpPWpGaD
Amantadine—SLC22A1—Neuronal System—HRAS—thyroid cancer	0.00011	0.000474	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—RXRA—thyroid cancer	0.000105	0.000453	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—PTCH1—thyroid cancer	0.000105	0.000451	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	0.000103	0.000442	CbGpPWpGaD
Amantadine—DDC—Metabolism—PTEN—thyroid cancer	0.000102	0.000439	CbGpPWpGaD
Amantadine—MAOB—Metabolism—PTGS2—thyroid cancer	9.83e-05	0.000424	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—RXRA—thyroid cancer	9.78e-05	0.000422	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—SST—thyroid cancer	9.58e-05	0.000413	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CALCA—thyroid cancer	9.22e-05	0.000397	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—TPR—thyroid cancer	9.12e-05	0.000393	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	9.12e-05	0.000393	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—PRKAR1A—thyroid cancer	8.97e-05	0.000387	CbGpPWpGaD
Amantadine—MAOB—Metabolism—PTEN—thyroid cancer	8.57e-05	0.000369	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CDK1—thyroid cancer	8.35e-05	0.00036	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	7.7e-05	0.000332	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—SLC5A5—thyroid cancer	6.83e-05	0.000294	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—NRG1—thyroid cancer	6.7e-05	0.000289	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—PPARG—thyroid cancer	6.63e-05	0.000286	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—PPARG—thyroid cancer	6.18e-05	0.000266	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—TERT—thyroid cancer	6.02e-05	0.000259	CbGpPWpGaD
Amantadine—DDC—Metabolism—AKT1—thyroid cancer	5.87e-05	0.000253	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—HIF1A—thyroid cancer	5.75e-05	0.000248	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—RXRA—thyroid cancer	5.73e-05	0.000247	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—PTGS2—thyroid cancer	5.21e-05	0.000225	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—NRAS—thyroid cancer	5.07e-05	0.000218	CbGpPWpGaD
Amantadine—MAOB—Metabolism—AKT1—thyroid cancer	4.94e-05	0.000213	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—PTGS2—thyroid cancer	4.86e-05	0.00021	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—BRAF—thyroid cancer	4.76e-05	0.000205	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—PTEN—thyroid cancer	4.55e-05	0.000196	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—KRAS—thyroid cancer	4.36e-05	0.000188	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—PTEN—thyroid cancer	4.24e-05	0.000183	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—HRAS—thyroid cancer	3.71e-05	0.00016	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—PPARG—thyroid cancer	3.62e-05	0.000156	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—AKT1—thyroid cancer	3.6e-05	0.000155	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CCND1—thyroid cancer	3.48e-05	0.00015	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—PTEN—thyroid cancer	3.36e-05	0.000145	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—AKT1—thyroid cancer	3.27e-05	0.000141	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—NRAS—thyroid cancer	2.99e-05	0.000129	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—PTGS2—thyroid cancer	2.85e-05	0.000123	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—AKT1—thyroid cancer	2.62e-05	0.000113	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—KRAS—thyroid cancer	2.58e-05	0.000111	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—PTEN—thyroid cancer	2.48e-05	0.000107	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—AKT1—thyroid cancer	2.44e-05	0.000105	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—TP53—thyroid cancer	2.29e-05	9.87e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—HRAS—thyroid cancer	2.19e-05	9.44e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—AKT1—thyroid cancer	1.93e-05	8.34e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—AKT1—thyroid cancer	1.43e-05	6.17e-05	CbGpPWpGaD
